发明名称 |
DP2 antagonist and uses thereof |
摘要 |
Described herein is the DP2 antagonist [2′-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4′-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP2 antagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D2-dependent or prostaglandin D2-mediated diseases or conditions. |
申请公布号 |
US8815917(B2) |
申请公布日期 |
2014.08.26 |
申请号 |
US201012846690 |
申请日期 |
2010.07.29 |
申请人 |
Panmira Pharmaceuticals, LLC |
发明人 |
Brittain Jason Edward;Stearns Brian Andrew;King Christopher David;Holme Kevin Ross |
分类号 |
A61K31/4418;A61K31/195;C07D213/64;C07C229/00 |
主分类号 |
A61K31/4418 |
代理机构 |
Wilson Sonsini Goodrich & Rosati |
代理人 |
Wilson Sonsini Goodrich & Rosati |
主权项 |
1. An oral solid dosage form pharmaceutical composition comprising:
a. about 1 mg, about 3 mg, about 10 mg, about 30 mg, or about 60 mg of [2′-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4′-trifluoromethyl-biphenyl-3-yl]-acetic acid, sodium salt; and b. at least one pharmaceutically acceptable excipient. |
地址 |
San Diego CA US |